By Dr. Layne McDonald In a promising development for the millions affected by Alzheimer's disease worldwide, researchers at King's College London have reported that an oral drug called KCL-286 successfully repaired DNA damage and reduced brain inflammation in a mouse model of Alzheimer's disease. The study, published in the peer-reviewed journal FEBS Open Bio, examined KCL-286, a first-in-class drug that activates the retinoic acid receptor-beta (RARβ) pathway. Originally dev
